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Group B streptococci (GBS) express various surface antigens designated c, R, and X antigens. A new R-like
surface protein from Streptococcus agalactiae strain Compton R has been identified by using a polyclonal
antiserum raised against the R protein fraction of this strain to screen a lambda Zap library. DNA sequence
analysis of positive clones allowed the prediction of the primary structure of a 105-kDa protein designated BPS
protein (group B protective surface protein) that exhibited typical features of streptococcal surface proteins
such as a signal sequence and a membrane anchor region but did not show significant similarity with other
known sequences. Immunogold electron microscopy using a BPS-specific antiserum confirmed the surface
location of BPS protein on S. agalactiae strain Compton R. Anti-BPS antibodies did not cross-react with R1 and
R4 proteins expressed by two variant type III GBS strains but reacted with the parental streptococcal strain
in Western blot and immunoprecipitation analyses. Separate R3 and BPS immunoprecipitation bands were
observed when a cell extract of strain Compton R was tested with an antiserum against Compton R previously
cross-absorbed to remove R4 antibodies. Immunization of mice with recombinant BPS protein by the subcu-
taneous route produced an efficient antigen-specific response, and immunized animals survived challenge with
a lethal dose of a virulent strain. Therefore, BPS protein represents a new R-like protective antigen of GBS.
Group B streptococci (GBS) have emerged as an important
cause of infection in neonates that is characterized by a high
mortality rate, even in developed countries (1). In the United
States alone, more than 15,000 cases and 1,300 deaths due to
GBS occur each year (46). The problem of GBS infection of
neonates lies in the fast and dramatic course of infection,
which can only be treated inadequately with antibiotics (13).
Since many women of child-bearing age have vaginal GBS
colonization, they are tested during pregnancy for carriage of
GBS (31). Besides affecting neonates, GBS cause a number of
maternal peripartum diseases and are responsible for serious
illness in nonpregnant adults (6). Necrotizing fasciitis and toxic
shock-like syndrome due to GBS have recently been reported
in adults (12).
GBS strains comprise nine serotypes based on the presence
of specific capsular polysaccharides. Of these, serotypes Ia, Ib,
II, III, and V have been most prevalent. Approximately 40% of
isolates in cases with invasive GBS disease express Ia polysac-
charide, and 27% express type III polysaccharide (24). In cer-
tain geographic areas, serotype V is emerging as the predom-
inant serotype (14, 19, 30). The occurrence of type V isolates,
however, increases with age, whereas that of other serotypes
decreases (14, 19, 30). Because of increasing antibiotic resis-
tance and the restriction of antibiotic therapy during preg-
nancy (33), it is desirable to develop alternatives to antibiotic
therapy. Clinical studies have shown that newborns whose
mothers have high titers of anti-GBS antibodies are seldom
infected (2). An attractive alternative to classic antibiotic ther-
apy could be vaccination of women of child-bearing age to
protect newborns against GBS infection (3). Since the GBS
capsule plays an important role in virulence, attempts have
been made to develop a vaccine based on capsular polysaccha-
rides. However, these vaccination studies have been unsuccess-
ful because of antigenic variation and the low immunogenicity
of capsular polysaccharides. A potential solution to this prob-
lem can be the use of glycoconjugates as candidate vaccines
(43).
Because of the suboptimal immunogenicity of capsule-based
vaccines, interest has shifted toward the surface protein anti-
gens of GBS as vaccine candidates or carrier proteins for
specific GBS polysaccharides. These antigens include the 
and  antigen of the c protein complex (17, 26), an -like
protein (20), the R proteins (10), and protein Rib (38). R
proteins are cell surface proteins of GBS that are resistant to
certain proteases (10). Four distinct species of R protein in
GBS have been described; of these, R4 is the predominant
species (10, 44). Most of the isolates of serotype III express R
proteins on the surface (10). In animal models, c protein an-
tigens are protective (40). The c protein antigens are expressed
by 90% of isolates of types Ia and Ib and by 50% of type II
invasive isolates; however, they are rarely expressed by type III
GBS (8). Rib protein also confers protective immunity in mice
(38). Other R proteins are also biologically important, and a
correlation between low levels of maternal antibodies to R
proteins and neonatal septicemia has been reported (25). An-
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other surface protein from type V GBS which shares N-termi-
nal sequence homology with the  antigen of c proteins has
been shown to confer protection against homologous challenge
(21). In this paper we describe a new R-like protein designated
BPS (group B protective surface protein) that is expressed by
a number of clinically relevant GBS serotypes and is a protec-
tive antigen in a mouse model.
MATERIALS AND METHODS
Bacterial strains, phages, plasmids, and media. GBS strains were from the
culture collection of the University of Minnesota (UM), Minneapolis. R protein
prototype strains were Compton R (nontypeable/R3, R4, BPS) (Compton 25/60,
NCTC 09828; J. Jelinkova, Prague, Czech Republic), 71-735 (III/R1) (Lancefield
D136C; R. Lancefield), and 76-043 (III/R4) (UM). Wild GBS strains were
H4A-0126 (Ia/R1, BPS), H4A-0148 (Ia,/R1, BPS) and B176 (Ia, BPS). The
Escherichia coli strains XL1-Blue MRF and XLOLR were obtained from a
commercial source (Stratagene). GBS were grown in Todd-Hewitt broth (Ox-
oid), while E. coli was grown in either NZY medium, Luria-Bertani medium
alone (34), or Luria-Bertani medium supplemented with 1 g of MgCl2/liter and
4 g of maltose/liter. Bacteria were grown at 37°C unless otherwise stated. Where
appropriate, E. coli was grown in the presence of 100 g of ampicillin/ml, 15 g
of tetracycline/ml, 50 g of kanamycin/ml, and 1 mM isopropyl--D-thiogalacto-
pyranoside (IPTG).
Antisera. Rabbit antisera included a polyvalent serum recognizing R3, R4, and
BPS (anti-Compton R from J. Jelinkova and UM), a divalent serum for R3 and
BPS (UM anti-Compton R absorbed with strain 76-043 to remove anti-R4),
monospecific anti-R3 (UM anti-Compton R absorbed with strains 76-043 and
H4A-0148 to remove anti-1, anti-R4, and anti-BPS), monospecific anti-R4 (pro-
duced with strain 76-043 [UM]), monospecific anti-R1 (produced with strain
71-735 [UM]), and anti-BPS (produced against the purified recombinant BPS
protein). Anti-R2 serum was not included in the studies because, to date, R2
protein has been expressed only by group A and C streptococci. This antiserum
does not recognize any surface protein in GBS lysates (10). For screening of the
gene library, a polyvalent serum raised against the purified surface R proteins of
Compton R was used.
Protein purification. For purification of cell surface R proteins from Strepto-
coccus agalactiae Compton R, a 1-liter shaken overnight culture was centrifuged
(at 10,000  g for 10 min) and the pellet was washed twice in 1.8% saline and
then resuspended to 0.33 g/ml (wet weight) in 50 mM glycine-NaOH (pH 11).
The pH was adjusted to 12 with 1 M NaOH. Alkali extraction of cell surface R
proteins was allowed to proceed for 2 h at 37°C with shaking. The suspension was
centrifuged (at 15,000  g for 20 min), and the supernatant was adjusted to pH
7 using 1 M HCl. The supernatant (15 ml) was concentrated to a 2-ml final
volume, and the buffer was changed against 20 mM Tris-HCl (pH 7.4) by using
a Centriprep-30 concentrator (Amicon) at 4°C. The preparation was applied to
a MonoQ HBPS/5 column (Pharmacia) with a flow rate of 1 ml/min using the
same buffer. R proteins were eluted from the column by using a 20-ml linear
NaCl gradient (0 to 0.4 M NaCl in 20 mM Tris-HCl). Fractions containing R
protein were detected by immunoblotting with an antiserum raised against S.
agalactiae Compton R whole cells. R protein-containing fractions were dialyzed
against 1/10-diluted phosphate-buffered saline (PBS), lyophilized, and then re-
suspended in an appropriate amount of 1/10-diluted PBS. Recombinant gluta-
thione S-transferase (GST)-tagged BPS protein was purified using glutathione-
agarose affinity chromatography according to the manufacturer’s instructions
(Pharmacia). A His-tagged BPS fusion protein was purified under native condi-
tions according to Qiagen protocols. Protein concentrations were determined by
the method of Bradford (4).
DNA manipulations. Chromosomal DNA from S. agalactiae Compton R was
isolated by the method of Talay et al. (39). Purified chromosomal DNA was
partially digested with the restriction enzyme Sau3AI and then subjected to NaCl
gradient centrifugation. Isolated 4- to 8-kb DNA fragments were cloned into the
BamHI site of Lambda Zap-Express-arms (Stratagene) according to the manu-
facturer’s instructions. The ligation mixture was packaged in vitro into lambda
heads and tails (Gigapack Gold 11; Stratagene) and transfected into E. coli XL-1
Blue MRF' according to the manufacturer’s instructions. Positive clones were in
vivo excised to form pBKCMV derivatives by using the helper strain E. coli
XLOLR in accordance with the Stratagene manual. Plasmid DNA was prepared
using the QIAwell plasmid extraction kit (Qiagen) and sequenced by the method
of Sanger et al. (35). Reactions were carried out using dye terminator ready
reaction mix (Perkin-Elmer), and products were processed in an ABI 373A DNA
sequencer (Applied Biosystems). For complete sequencing of both strands of the
DNA analyzed, universal and internal primers were generated and used to
initiate sequencing of DNA. Sequence analysis was undertaken using GENMON
4.4 software (German Research Center for Biotechnology). The PCR using the
5-BamHI primer 5-TTACATCTGGATCCACTCCAACAGGTG-3 and the
3-SmaI primer 5TAGTTGGAACCCGGGATTTATTGGTTGG-3 was per-
formed in a thermocycler (MWG Biotech); the resulting PCR fragment was
cloned into the BamHI and SmaI sites of the pGEX2T expression vector (Phar-
macia) and then induced with IPTG by standard procedures (34). For the
His-tagged BPS fusion protein, the gene was cloned into pQE30 (Qiagen),
overexpressed, and purified by a previously described method (29).
SDS-PAGE and Western blot analysis. Sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) was performed as described by Laemmli (22),
and the gel was then stained with Coomassie brilliant blue R250 (Sigma).
Prestained high-molecular-weight markers were used to determine the apparent
molecular weights of proteins (Sigma). Alternatively, Western blotting of pro-
teins electroeluted onto Immobilon P membranes (Millipore) was performed
essentially as described by Burnette (5).
Immunoelectron microscopy. For preembedment labeling of the BPS protein,
bacteria were grown in Todd-Hewitt broth overnight, centrifuged, and resus-
pended in 500 l of PBS (50 mM (each) potassium phosphate and sodium
phosphate and 0.15 M NaCl [pH 6.9]). Fifty microliters of protein A-purified
anti-BPS antibodies (2.7 mg of immunoglobulin G [IgG] protein/ml) was added,
and samples were incubated at 37°C for 1 h. Antibodies purified from preim-
mune serum as well as anti-GST antibodies served as controls. After three
washing steps with PBS, samples were resuspended in 500 l of PBS, and 20 l
of protein A colloidal gold (diameter, 10 nm; British BioCell, Cardiff, United
Kingdom) was added. After incubation for 30 min at 37°C and several washing
steps, samples were fixed with 3% glutaraldehyde and 5% formaldehyde in PBS
for 1 h on ice. Subsequently, they were postfixed with 1% aqueous osmium
tetroxide for 1 h at room temperature. After the samples were embedded in 1.5%
agar, they were dehydrated in a graded series of acetone and embedded by use
of Spurr resin (37). After polymerization at 70°C for 8 h, ultrathin sections were
cut with a diamond knife, and sections were poststained with uranyl acetate and
lead citrate before examination with a Zeiss transmission electron microscope
(TEM910) at an acceleration voltage of 80 kV.
For postembedment labeling, bacteria were fixed with 0.2% glutaraldehyde
and 0.5% formaldehyde in PBS for 1 h on ice. After a wash in PBS containing
0.01 M glycine, samples were dehydrated with a graded series of ethanol and
embedded in LRWhite resin (London Resin Company, Berkshire, United King-
dom). After polymerization at 50°C for 24 h, ultrathin sections were cut and
collected onto Formvar-coated 300-mesh nickel grids. Sections were then incu-
bated on drops of the anti-BPS antibodies (100 g of IgG protein/ml) for 12 h at
4°C. After a wash with PBS, sections were incubated on drops of 0.4% skim milk
in water for 5 min, blotted dry on filter paper, and incubated on drops of a
1:100-diluted protein A colloidal gold stock solution (diameter of gold particles,
10 nm) for 30 min. After a wash in PBS containing 0.01% Tween 20, sections
were counterstained with 4% aqueous uranyl acetate for 5 min before examina-
tion with the electron microscope.
Immunoprecipitation reactions in agarose. R proteins from GBS strains were
detected in agarose slides by Ouchterlony double-diffusion (DD) immunopre-
cipitation using Lancefield hot HCl or 0.1% trypsin cell extracts (11). To examine
the susceptibilities of the various R proteins to trypsin or pepsin digestion, HCl
or 0.1% trypsin cell extracts were treated (1 h at 37°C; pH 8.2) either with 5 or
0.2% trypsin or with 0.5 or 0.2% pepsin (pH 2.0 and 4.0, respectively) (11, 38, 44,
45). Enzyme-treated or control (buffer only) samples were then tested to deter-
mine the effects of such treatments on the immunoprecipitation reactions.
Immunization and protection studies. Four-week-old female BALB/c (H-2d)
mice (Harlan Winkelmann) were immunized with recombinant BPS protein on
days 1, 3, 6, and 27 (30 g/dose) by the subcutaneous route with aluminum
phosphate (Adju-Phos; Axell Accurate Chemical & Scientific Corp.) as the
adjuvant. Groups of immunized and control animals (n  9) were challenged on
day 37 with an inoculum of the streptococcal strain Compton R corresponding to
the 80% lethal dose (LD80; 5  108 bacteria/ml) in nonimmunized mice, and
mortality was recorded daily.
ELISA. Serum samples were collected on day 36 and monitored for BPS-
specific antibodies by an enzyme-linked immunosorbent assay (ELISA). Briefly,
96-well Immuno MaxiSorp assay plates (Nunc, Roskilde, Denmark) were coated
with 50 l of BPS/well (5 g/ml) in coating buffer (bicarbonate, pH 8.2). After
overnight incubation at 4°C, plates were blocked with 10% fetal calf serum in
PBS for 1 h at 37°C. Serial twofold dilutions of serum in 10% fetal calf serum-
PBS were added (100 l/well), and plates were incubated for 2 h at 37°C. After
four washes with PBS–0.05% Tween 20, secondary antibodies were added (bio-
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tinylated -chain-specific goat anti-mouse IgM and -chain-specific goat anti-
mouse IgG [Sigma]) and incubated for a further 2 h at 37°C. After four washes,
100 l of peroxidase-conjugated streptavidin (PharMingen) was added to each
well and plates were incubated at room temperature for 1 h. After four washes,
reactions were developed using ABTS [2,2-azinobis(3-ethylbenzthiazoline-6-sul-
fonic acid)] in 0.1 M citrate-phosphate buffer (pH 4.35) containing 0.01% H2O2.
Results were expressed as end point titers and correspond to the last dilution
which gave an optical density at 405 nm (OD405) of 0.1 U above the OD405 of
negative controls after a 10-min incubation.
Nucleotide sequence accession number. The sequence of the gene encoding
the BPS protein of GBS has been assigned EMBL accession number AJ133114.
RESULTS
Purification of cell surface R proteins from S. agalactiae
Compton R. The purified product obtained after alkaline ex-
traction and fast protein liquid chromatography anion-ex-
change chromatography gave four bands of 125, 120, 115, and
110 kDa in a silver-stained SDS-PAGE gel. Western blot anal-
ysis indicated that all bands were immunoreactive against poly-
clonal reference R antiserum, with the 125- and 120-kDa bands
reacting most prominently. Since the antiserum used was gen-
erated against all surface R proteins, it is likely that the less
prominent 115- and 110-kDa bands represented other R pro-
teins; this, however, could not be determined, because the
antisera used could not differentiate between R3 and R4. Al-
kaline extraction in the presence of protease inhibitors or fur-
ther purification by gel filtration did not change the gel pattern.
These purified proteins were used to raise a polyclonal anti-
serum for screening of the gene library.
Cloning and nucleotide sequence analysis of the gene en-
coding BPS protein. A lambda Zap gene library of S. agalactiae
Compton R chromosomal DNA was screened using a poly-
clonal antiserum raised against purified cell surface R proteins
isolated from the homologous strain. One clone, which ex-
pressed a protein with an apparent molecular size of 125 kDa
that was reactive against the antiserum, was designated pSE3.
The 5.0-kb DNA insert of the plasmid was subjected to DNA
sequence analysis, which revealed a single open reading frame
of 2,937 bp encoding a predicted 105-kDa protein (Fig. 1). A
putative Shine-Dalgarno sequence (5-GAGGAAG-3) was
detected 5 bp upstream of the ATG start codon. Both 	35
(5-TTGGAT-3) and 	10 (5-TATAAT-3) consensus se-
quences at least typical for E. coli were detected 94 and 66 bp
upstream of the open reading frame, respectively. A putative
39-amino-acid signal sequence was detected at the amino ter-
minus of the putative protein and shared DNA similarity with
other gram-positive cell surface protein signal sequences (41).
The carboxy terminus of the protein contained an LPXTG
consensus motif typical of membrane-anchored surface pro-
teins of many streptococci and other gram-positive bacteria (9,
15). Within the carboxy-terminal half of the protein, two iden-
tical repeats of 76 amino acids each, separated by a 101-amino-
acid spacer region, were found. After a search of the EMBL
database, the protein was found to share limited DNA simi-
larity only with the protein of unknown function encoded by
the Streptococcus suis mrp gene (36). The R protein analyzed in
this study, which was present in cell surface extracts of S.
agalactiae Compton R, was immunologically distinct from R1,
R3, and R4 (see below) and was thus designated BPS.
Expression and purification of GST-tagged BPS. By use of
the 5-BamHI and 3-SmaI primers, the bps gene was PCR
amplified, excluding coding regions for the amino-terminal
signal sequence and carboxy-terminal membrane anchor re-
gion, and ligated into the relevant enzyme restriction sites of
the pGEX-2T expression vector (Pharmacia) to form pSE4.
Induction of E. coli XL1-Blue MRF (pSE4) resulted in the
expression of GST-tagged BPS with an apparent molecular
size of 158 kDa, which was subsequently purified using gluta-
thione-agarose affinity chromatography (Fig. 2A). The purified
recombinant GST-BPS fusion protein was used to raise a poly-
clonal rabbit antiserum which recognized the degraded BPS
protein with an apparent molecular size of 125 kDa in S.
agalactiae Compton R whole-cell extracts, the GST with an
apparent molecular size of 32 kDa in E. coli XL1-Blue MRF
(pGEX-2T) whole-cell extracts, and the158-kDa degraded re-
combinant BPS fusion protein in E. coli XL1-Blue MRF
(pSE4) whole-cell extracts (Fig. 2B, lanes 1 to 3, respectively).
A commercially acquired anti-GST monoclonal antibody re-
acted against GST and GST-tagged BPS, but not against native
BPS, in S. agalactiae Compton R whole-cell extracts (data not
shown).
Western blot analysis using anti-BPS serum. Western blot
analysis using BPS antiserum revealed that BPS antigen pro-
duced by S. agalactiae Compton R, partially purified Compton
R surface proteins, and purified recombinant GST-tagged BPS
are degraded following sample preparation, resulting in detec-
tion of multiple bands (Fig. 2C, lanes 1, 2, 4, and 6). However,
the lack of reactivity of the BPS antiserum against E. coli
XL1-Blue MRF confirms the lack of cross-reactive antibodies
and the purity of the GST-tagged BPS preparation used to
prepare the polyclonal antiserum (Fig. 2C, lane 1).
The BPS antiserum was also used to detect BPS in a number
of different GBS serotypes. The lack of reactivity of the anti-
serum with S. agalactiae 71-735 (serotype III/R1; Fig. 2C, lane
3) and 76-043 (serotype III/R4; lane 5) revealed that BPS was
not immunologically related to R1 and R4. S. agalactiae H4A-
0126 (serotype Ia/R1), on the other hand, did express a protein
of higher apparent molecular weight which was reactive with
the BPS antiserum and produced a degradation profile similar
to that of Compton R, suggesting that H4A-0126 also ex-
pressed BPS, that the BPS antigen displayed size variation, and
that BPS was expressed in more than one serotype of S. aga-
lactiae (Fig. 2C, lane 4). Further proof of the immunological
distinction between R1, R3, R4, and BPS was the fact that the
antiserum to R3 and BPS from Compton R did not react with
proteins from strain 71-735 or 76-043 (Fig. 2C, lanes 3 and 5).
Cell surface expression of BPS in S. agalactiae Compton R.
To confirm and characterize the location of BPS protein on the
surfaces of S. agalactiae cells, immunoelectron microscopy was
conducted by using a monospecific polyclonal anti-BPS anti-
serum. Immunogold particles were found to be evenly distrib-
uted on the cell surface of the parental S. agalactiae strain
Compton R by pre- as well as postembedding techniques (Fig.
3A, C, and D). This indicates that BPS protein is homoge-
neously expressed on the cellular surface. No labeling was
found in bacterial cytoplasm. A GBS isolate(76-043/III/R4)
that does not express the BPS protein exhibited only a very few
gold particles bound to the surface (Fig. 3B). Anti-GST anti-
bodies as well as preimmune serum were used as controls and
did not reveal any labeling (data not shown).
Ouchterlony DD analysis of S. agalactiae Compton R pro-
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FIG. 1. Nucleotide sequence and deduced amino acid sequence of the gene encoding the BPS protein of GBS (EMBL accession number:
AJ133114). Putative 	10 and 	35 sequences are boxed, and the Shine-Dalgarno region is underlined. Within the BPS coding region, the initial
codons of the two repeats are boxed and the regions coding for the LPXTG membrane anchor consensus sequence and the charged C-terminal
tail are underlined. Amino acids are given in one-letter code.
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teins with different antisera. Identification of the cloned BPS
protein as a R-like protein was based on DD studies of strain
Compton R with reference antisera. Figure 4A shows that the
HCl extract of strain Compton R (center well), tested with a
UM antiserum to Compton R (well 1), gave three separate
precipitin bands, with the diffuse R4 band closest to the anti-
serum well, the dense R3 band in the middle, and the lighter
BPS band very close to the R3 band and farthest away from the
antiserum well. Anti-Compton R sera from Prague and UM
placed in adjacent wells showed the same three precipitin
bands, but the BPS band was lighter and closer to R3 with the
Prague antiserum than with the UM antiserum (data not
shown). When the anti-Compton R was absorbed to remove
anti-R4 antibodies (wells 2 and 5), only the R3 and BPS bands
were seen. When the anti-Compton R serum was absorbed to
remove anti-R4 and anti-BPS antibodies (well 4), only R3 was
left. BPS antiserum produced with the recombinant protein
(wells 3 and 6) gave one precipitin band, and this band gave a
reaction of identity with the BPS band of the antiserum to
Compton R produced with whole bacterial cells (wells 1, 2, and
5). In addition, when an antiserum to BPS protein was placed
in the center well, a precipitin reaction of identity was observed
with the purified recombinant protein and the HCl extract of
strain Compton R, while the extracts of strains 71-735 (III/R1)
and 76-043 (III/R4) did not react with this antiserum (data not
shown).
Enzyme susceptibility studies of the BPS from S. agalactiae
Compton R. To compare the enzyme susceptibility of BPS to
that of R3, the HCl extract of Compton R was treated with
trypsin or pepsin and then compared by DD to buffer-treated
controls. Figure 4B shows the R3 (inside, denser) and BPS
(outer, lighter) precipitin bands of the untreated extract (well
1) when the antiserum to R3 and BPS was placed in the center
well. Treatment with 0.02% trypsin did not affect the BPS and
R3 reactions. Treatment of the extract with 0.2% trypsin (well
5), however, eliminated BPS but did not affect the R3 reaction,
while 5% trypsin greatly diminished the R3 reaction (well 4).
By contrast, only the BPS precipitin band remained after treat-
ment with 0.2% pepsin at pH 4 (well 3), and neither the R3 nor
the BPS reaction was seen after treatment with 0.5% pepsin at
pH 2, the optimum and conventional pH for pepsin activity
(data not shown). Buffer only at pH 8, pH 4, or pH 2 (data not
shown) did not affect either the R3 or the BPS precipitin band.
Vaccination with BPS protein protects mice against chal-
lenge with virulent strains of GBS. For immunization studies,
His-tagged BPS was used to avoid the immune-modulatory
effects of GST. The gene encoding the whole BPS protein was
cloned into the pQE30 expression vector, and His-tagged pro-
tein was purified by affinity chromatography. Immunization of
mice with recombinant BPS protein by the subcutaneous route
triggered the elicitation of a very efficient antigen-specific re-
sponse (Fig. 5A). When the immunized animals were chal-
lenged with strain Compton R, approximately 88% of the vac-
cinated animals survived (Fig. 5B), whereas mice in the control
group were not protected (78% lethality).
DISCUSSION
In spite of advances in diagnosis and treatment, GBS infec-
tions remain a major cause of neonatal mortality and morbid-
ity. Development of an effective vaccine to prevent GBS dis-
ease through maternal immunization seems to be a promising
strategy for the control of GBS infections. A prerequisite for
the development of an effective vaccine is the identification
and characterization of potential cell surface targets for ther-
apeutic intervention. Because of the suboptimal potential of
capsular polysaccharides, interest has shifted to protein anti-
gens as components of vaccine candidates. A number of sur-
face proteins such as  antigen (17, 18),  protein (27), protein
Rib (38), and R proteins (10, 11) have been described. Most of
these protein antigens have been shown to be protective either
by contributing toward resistance to opsonization (32) or by
eliciting protective immunity (21, 27). Elicitation of protection
against encapsulated GBS strains (23) underlines the impor-
tance of GBS surface proteins as vaccine candidates. In this
report we describe yet another GBS R-like surface protein that
was cloned from strain Compton R; sequence analysis showed
that it possesses all the typical features of gram-positive surface
proteins such as the signal sequence (41) and the membrane
anchor, which contains the sequence LPXTG (9). The surface
location was confirmed by immunoelectron microscopy. Se-
quence analysis showed no similarity on a protein level with
FIG. 2. (A) Recombinant expression of GST-tagged BPS in E. coli
XL 1-Blue MRF and purification by glutathione-agarose affinity chro-
matography. The Coomassie-stained gel shows E. coli whole-cell ex-
tracts prior to induction (lane 1) and after induction (lane 2) and
purified recombinant BPS fusion protein (lane 3). (B) Western blot
analysis of whole-cell lysates of GBS strain Compton R (lane 1), E. coli
XL 1-Blue MRF harboring plasmid pGEX2T (lane 2), and E. coli XL
1-Blue MRF harboring plasmid pSE4 (lane 3) using a polyclonal
antiserum raised against purified recombinant GST-BPS fusion pro-
tein. (C) Western blot analysis of purified recombinant BPS protein as
well as whole-cell extracts of GBS and E. coli using BPS antiserum.
Lane 1, purified recombinant BPS; lane 2, Compton R; lane 3, 71-735
(serotype III/R1); lane 4, H4A-0126 (type Ia/R1, BPS); lane 5, 76-043
(type III/R4); lane 6, E. coli XL1-Blue expressing BPS; lane 7, E. coli
XL1-Blue control.
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any known GBS proteins, indicating that this is a novel surface
protein; therefore, it was designated BPS. The protein consists
of 979 amino acids and contains two identical repeats of 76
amino acids separated by a 101-amino-acid spacer in the C-
terminal region. BPS, therefore, belongs to a family of GBS
surface proteins with repetitive structures (42). Two other
members of this family, namely, protein Rib (38) and  protein
(28), are also trypsin resistant and give a ladder-like pattern
similar to the BPS pattern in SDS-PAGE and Western blot
analysis. BPS, however, showed no sequence similarity to pro-
tein Rib or  protein. On the protein level, BPS shows some
similarity (26% identity) to the mrp gene from S. suis (36). The
function of the mrp gene product is not yet known.
To determine the prevalence of BPS, the protein was ex-
pressed as a fusion, purified, and used to raise a polyclonal
antiserum. Immunoprecipitation in agarose was useful to de-
termine that BPS was indeed an integral surface antigen of S.
agalactiae Compton R and to identify it as a unique protein,
separate from R3 and R4 proteins. In early (44) and subse-
quent (10) work on the R proteins of GBS, strain Compton R
was identified as having only R3 and R4 proteins. When we
tested our HCl extracts with Prague anti-Compton R serum,
which was used in those studies, the BPS precipitin reaction
was weak and practically fused with that of R3, making it
difficult to recognize them as two distinct lines. However, sep-
aration and identification of three separate proteins in the HCl
and trypsin extracts of Compton R were possible with our new
polyclonal rabbit antiserum. Comparison of the reactions ob-
tained with our new antiserum with those obtained with the
antiserum from Prague showed that, although they were some-
what obscured, the Prague antiserum also contained antibodies
to BPS (data not shown). This further confirmed that BPS is a
new protein that is separate from R3 and R4, the previously
recognized proteins of Compton R.
FIG. 3. Immunoelectron microscopy of S. agalactiae Compton R using a monospecific BPS antiserum. Preembedment labeling studies (A and
C) clearly demonstrate that BPS protein is located at the bacterial surface. A ring of gold-particles (black dots) can be found on the outer edge
of the bacterial cell wall. The control strain (76-043/III/R4), which does not express the BPS protein, exhibits only a very few gold particles (B,
arrows). Postembedding (D) also reveals that BPS protein is exclusively located on the bacterial surface despite the fact that less labeling could
be detected due to loss of antigenicity during fixation, dehydration, and embedding. Almost no labeling was found in the bacterial cytoplasm. Bars,
250 nm.
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The results from the enzyme digestion studies provided ad-
ditional support for the fact that BPS is a separate protein of
Compton R. DD results indicated that mild trypsin treatment
affected BPS more than R3. In contrast, the results from mild
pepsin treatment of BPS at suboptimal conditions (pH 4) in-
dicated that R3 was more pepsin susceptible than BPS. This
reduced susceptibility of BPS to pepsin digestion is similar to
that of R4 protein (11) and protein Rib, since treatment with
pepsin at suboptimal pH conditions was used to characterize
the latter and to compare it to the  component of the c
protein (38), another trypsin-resistant protein of GBS (7).
Finding BPS in GBS strains such as H4A-0126 and H4A-
0148 demonstrates that this protein of Compton R is found in
wild GBS strains of other serotypes and protein profiles. Our
results from examination of 1,627 human GBS isolates by dou-
ble immunodiffusion and Southern hybridization indicated that
BPS was found in 7.4% of serotype Ia/R1 isolates. 6.8% of
serotype II isolates, and 5% of serotype V isolates (A. E.
Flores, S. Erdogan, G. S. Chhatwal, C. J. Baker, S. Hillier, and
P. Ferrieri, Abstr. XIVth Lancefield Int. Symp. Streptococci
Streptococcal Dis., abstr. O2.8, 1999). The presence of both R1
and BPS in the serotype Ia isolates was analogous to the
presence of both R1 and R4 in the majority of serotype V
isolates (8). Furthermore, these results indicated that BPS was
a marker found in recently isolated colonizing human isolates
and that, as such, it may be useful in their characterization (7).
The results obtained demonstrated that the BPS protein is
an antigen able to confer protective immunity against GBS. In
order to evaluate whether the BPS protein can also confer
protection against challenge with a heterologous strain, immu-
nized animals were challenged with strain B176 (Ia, BPS).
While 67% of the vaccinated animals survived, only 22% of the
FIG. 4. (A) Identification of the surface proteins of S. agalactiae
Compton R by immunodiffusion in agarose slides. Center well, HCl
extract of the GBS Compton R strain; well 1, antiserum to the R3, R4,
and BPS proteins of Compton R; wells 2 and 5:,antiserum to the R3
and BPS proteins of Compton R; wells 3 and 6, antiserum to the
recombinant BPS protein (anti-BPS); well 4, antiserum to the R3
protein from Compton R. (B) Effect of enzyme treatment (1 h at 37°C)
on the immunoprecipitation reactions of the R3 and BPS proteins
from the HCl extract of S. agalactiae Compton R. Center well, anti-
serum to the R3 and BPS proteins of Compton R; well 1, untreated
HCl extract; well 2, pH 4 buffer control; well 3, extract treated with
0.2% pepsin (pH 4); well 4, extract treated with 5% trypsin (pH 8); well
5, extract treated with 0.2% trypsin; well 6, pH 8 buffer control.
FIG. 5. Vaccination with the BPS protein triggers the elicitation of
a protective response. (A) BPS-specific serum antibodies in mice as
determined by ELISA after subcutaneous immunization with the BPS
protein. Results are expressed as the geometric mean end point titers
(GMT). Error bars, standard errors of the means.(B) Survival times of
vaccinated and nonvaccinated mice after challenge with GBS. Animals
were challenged with an inoculum of strain Compton R corresponding
to the LD80 at day 37 after the primary immunization, and mortality
was recorded daily. The differences in survival observed between im-
munized and control animals were statistically significant (P  0.05).
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mice in the control group survived (data not shown). These
results confirmed that immunization with the BPS protein can
also protect against heterologous challenge (P  0.05).
Considering that the natural portal of entry for GBS is the
mucosa from the respiratory and genitourinary tracts, it seems
particularly attractive to stimulate not only an efficient systemic
but also a local mucosal response following vaccination. This
may lead to a more efficient protection of newborns by two
different mechanisms, namely, (i) passive transfer of maternal
antibodies leading to protection against disease and (ii) reduc-
tion of the risk of maternal colonization (i.e., infection) by the
presence of vaginal antibodies. Of importance is the fact that
BPS elicits a strong IgG response; this isotype can cross the
placenta and therefore may provide passive protection. It has
also been demonstrated that due to the existence of a mucosal
network, coadministration of vaccine antigens and mucosal
adjuvants by the intranasal route can lead to the elicitation of
local responses in the urogenital tract (16). Preliminary studies
from our group confirmed that protective immunity can also be
achieved following vaccination by the intranasal route with the
BPS protein in combination with the cholera toxin B subunit as
a mucosal adjuvant.
Different serotypes of GBS express different surface pro-
teins, which can become targets for the elicitation of a protec-
tive immune response. An effective vaccine, therefore, should
contain more than a single antigen in order to confer protec-
tion against predominant circulating serotypes. Thus, BPS pro-
tein, which is expressed by isolates of serotypes Ia, II, and V,
may represent an attractive candidate antigen for incorpora-
tion in anti-GBS vaccine formulations.
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